Bayer's Hyrnuo Receives FDA Approval for HER2-Mutated Non-Small-Cell Lung Cancer
核心洞察
Bayer's Hyrnuo (搜索) (sevabertinib (搜索)) has received FDA approval as an oral HER2 (搜索)-directed therapy for adults with advanced HER2-mutant non-small-cell lung cancer who have received prior systemic therapy.
The drug targets tumors with HER2 (搜索) (ERBB2 (搜索)) tyrosine kinase domain activating mutations and was granted breakthrough therapy designation in February.
Thermo Fisher Scientific (搜索)'s Ion Torrent Oncomine Dx Target Test serves as the companion diagnostic for Hyrnuo (搜索), enabling precise patient selection for treatment.
Bayer AG has secured FDA approval for Hyrnuo (搜索) (sevabertinib (搜索)), a reversible tyrosine kinase inhibitor designed to treat adults with advanced HER2 (搜索)-mutant non-small-cell lung cancer (NSCLC). The oral therapy represents a significant advancement for patients with this specific genetic subtype of lung cancer.
Targeted Therapy for Specific Mutations
The FDA approval specifically covers patients whose tumors harbor HER2 (搜索) (ERBB2 (搜索)) tyrosine kinase domain (TKD) activating mutations and who have previously received systemic therapy. This targeted approach addresses a well-defined patient population with limited treatment options.
The drug, previously designated as BAY-2927088, received breakthrough therapy designation from the FDA in February, recognizing its potential to address an unmet medical need. The regulatory pathway was expedited through priority review, with the priority New Drug Application accepted by the FDA in May.
Companion Diagnostic Integration
Thermo Fisher Scientific (搜索)'s Ion Torrent Oncomine Dx Target Test has been approved as the companion diagnostic for Hyrnuo (搜索). This diagnostic tool enables healthcare providers to identify patients with the specific HER2 (搜索) mutations that make them candidates for treatment with the new therapy.
The integration of a companion diagnostic ensures precise patient selection, allowing clinicians to identify those most likely to benefit from Hyrnuo (搜索) treatment based on their tumor's genetic profile.
Regulatory Timeline and Designation
The approval follows a streamlined regulatory process that began with breakthrough therapy designation in February. The FDA's decision to grant this designation reflected the agency's recognition of Hyrnuo (搜索)'s potential to provide substantial improvement over existing treatments for this patient population.
The priority review designation further accelerated the approval timeline, demonstrating the FDA's commitment to bringing innovative therapies to patients with limited treatment options in the HER2 (搜索)-mutated NSCLC space.